The Lancet Infectious Diseases Publishes Rifasutenizol for H. pylori Phase I/II Clinical Trial Results
Suzhou China, February 14, 2024 – TenNor Therapeutics and the First Hospital of Jilin University jointly published a research article in The Lancet Infectious Diseases (Lancet ID), reporting the phase I/II clinical trial results of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The journal also published a commentary on the research by leading experts in the field.